Dupont Capital Management Corp lessened its position in Alkermes plc (NASDAQ:ALKS – Free Report) by 87.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,779 shares of the company’s stock after selling 11,902 shares during the period. Dupont Capital Management Corp’s holdings in Alkermes were worth $50,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Neo Ivy Capital Management purchased a new stake in shares of Alkermes during the second quarter worth about $27,000. China Universal Asset Management Co. Ltd. lifted its holdings in Alkermes by 33.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 2,227 shares of the company’s stock worth $63,000 after buying an additional 558 shares during the period. Lazard Asset Management LLC bought a new stake in shares of Alkermes in the 1st quarter worth approximately $72,000. Federated Hermes Inc. increased its stake in shares of Alkermes by 31.2% during the third quarter. Federated Hermes Inc. now owns 4,166 shares of the company’s stock valued at $93,000 after buying an additional 991 shares during the period. Finally, State of Wyoming bought a new position in shares of Alkermes during the fourth quarter valued at approximately $115,000. Hedge funds and other institutional investors own 99.39% of the company’s stock.
Alkermes Price Performance
Shares of ALKS opened at $31.92 on Friday. The firm’s 50-day simple moving average is $30.89 and its two-hundred day simple moving average is $28.97. Alkermes plc has a fifty-two week low of $21.75 and a fifty-two week high of $33.71. The stock has a market cap of $5.30 billion, a PE ratio of -32.24 and a beta of 0.62. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.88 and a current ratio of 2.25.
Analyst Ratings Changes
Several research firms recently weighed in on ALKS. HC Wainwright lifted their price target on shares of Alkermes from $32.00 to $34.00 in a report on Thursday, April 27th. Mizuho boosted their price target on shares of Alkermes from $36.00 to $40.00 in a research report on Wednesday, June 7th. StockNews.com began coverage on shares of Alkermes in a report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alkermes in a report on Monday, July 10th. Finally, JPMorgan Chase & Co. raised their target price on Alkermes from $29.00 to $31.00 in a research note on Tuesday, April 25th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.33.
Insider Activity
In related news, Director Nancy Wysenski sold 41,250 shares of the company’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $31.24, for a total value of $1,288,650.00. Following the transaction, the director now owns 15,829 shares in the company, valued at approximately $494,497.96. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Nancy Wysenski sold 41,250 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $31.24, for a total value of $1,288,650.00. Following the transaction, the director now directly owns 15,829 shares of the company’s stock, valued at approximately $494,497.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cato T. Laurencin sold 2,800 shares of Alkermes stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $31.50, for a total value of $88,200.00. Following the completion of the sale, the director now directly owns 7,479 shares of the company’s stock, valued at approximately $235,588.50. The disclosure for this sale can be found here. Insiders sold 71,184 shares of company stock worth $2,161,837 over the last three months. 4.76% of the stock is currently owned by corporate insiders.
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer.
See Also
- Five stocks we like better than Alkermes
- U.S. Bancorp Shares Rally As Analysts Get Bullish After Q2 Report
- AutoNation Beats Earnings Expectations, Stock Down?
- American Express Hiccups After Earnings, Time To Buy?
- ISRG Stock Sinks After Strong Earnings: Is the Growth Priced In?
- Winners And Losers In The Oilfield Supercycle
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
